Related Experiment Video

Updated: Jul 5, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

MDM2 SNP309 and TP53 Arg72Pro interact to alter therapy-related acute myeloid leukemia susceptibility

Nathan A Ellis1, Dezheng Huo, Ozlem Yildiz

  • 1Department of Medicine, University of Chicago Cancer Research Center, University of Chicago, IL 60637, USA.

Blood
|April 23, 2008
PubMed

Insights

Genetic variations in the p53 pathway, specifically MDM2 and TP53 polymorphisms, interact to influence the risk of therapy-related acute myeloid leukemia (t-AML). This interaction affects susceptibility to genotoxic therapies.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • The p53 tumor suppressor is crucial for cellular responses to DNA damage.
  • p53 pathway alterations are implicated in the development of therapy-related acute myeloid leukemia (t-AML).
  • Constitutional genetic variations in the p53 pathway may impact t-AML risk.

Purpose of the Study:

  • To investigate the association between common functional p53-pathway variants and t-AML risk.
  • To examine the interaction between MDM2 SNP309 and TP53 codon 72 polymorphisms in t-AML pathogenesis.

Main Methods:

  • Genotyping of 171 t-AML patients for MDM2 SNP309 and TP53 codon 72 polymorphisms.
  • Statistical analysis to assess individual and interactive effects of these variants on t-AML risk.
  • Subgroup analysis based on treatment modality (chemotherapy vs. radiotherapy) and cytogenetic abnormalities.

Main Results:

  • Neither MDM2 SNP309 nor TP53 codon 72 polymorphism alone significantly affected t-AML risk.
  • A significant interaction was observed: individuals with specific combined genotypes (MDM2 TT/TP53 Arg/Arg or MDM2 G allele/TP53 Pro allele) had increased t-AML risk (P interaction = .009).
  • This interactive effect was prominent in patients treated with chemotherapy and those with chromosome 5/7 loss, suggesting a link to alkylator chemotherapy exposure.

Conclusions:

  • Constitutional genetic variations in MDM2 and TP53 interact to modulate the risk of developing t-AML.
  • These interacting variants are determinants of susceptibility to genotoxic therapies and subsequent t-AML development.
  • Understanding these genetic interactions can inform personalized risk assessment for patients undergoing genotoxic treatments.

More Related Videos

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Mismatch Repair01:20

Mismatch Repair

Organisms are capable of detecting and fixing nucleotide mismatches that occur during DNA replication. This sophisticated process requires identifying the new strand and replacing the erroneous bases with correct nucleotides. Mismatch repair is coordinated by many proteins in both prokaryotes and eukaryotes.
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.